86 episodes

The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland, Ph.D., covering a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.

The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends.

The Onco'Zine Brief Peter Hofland, Ph.D

    • Science
    • 3.0 • 2 Ratings

The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland, Ph.D., covering a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.

The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends.

    Antibody-drug Conjugates: Coming of Age

    Antibody-drug Conjugates: Coming of Age

    In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors of Sutro Biopharma (www.sutrobio.com)

    Sutro is a clinical-stage drug discovery, development, and manufacturing company using precise protein engineering and rational design to advance the development of the next-generation oncology therapeutics for unmet medical needs and areas where the current standard of care is suboptimal.

    To date, Sutro’s technology platform has led to the development of cytokine-based immuno-oncology therapies, antibody-drug conjugates or ADCs, vaccines, and bispecific antibodies.
    In addition to Sutro’s own pipeline of novel drugs, including STRO-001, a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma, and STRO-002, a folate receptor alpha (FolRα)-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers, the company is also collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.

    Antibody-drug conjugates like STRO-001 and STRO-002, are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

    Today there are 10 approved ADC on the market – and many more in development. And as a result, ADCs have become a powerful class of therapeutic agents in oncology and hematology.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 46 min
    Harnessing the Immune System to Fight Cancer: An Interview with Innate Pharma's Mondher Mahjoubi, MD.

    Harnessing the Immune System to Fight Cancer: An Interview with Innate Pharma's Mondher Mahjoubi, MD.

    In this edition of The Onco’Zine Brief Peter Hofland, Ph.D., talks with Mondher Mahjoubi, MD, Chief Executive Officer and Chairman of the Executive Board of Innate Pharma, a clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

    Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical needs. The company, based in the South of France, has been a pioneer in the understanding of the biology of natural killer (NK-) cell, and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk, Sanofi, and a multi-products collaboration with AstraZeneca.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 38 min
    Shaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony Polverino, PhD

    Shaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony Polverino, PhD

    In this edition of The Onco’Zine Brief Peter Hofland, Ph.D talks with Tony Polverino, PhD. In September 2918 Polverino joined Zymeworks, a clinical-stage, biopharmaceutical company developing next-generation multifunctional biotherapeutics. He currently serves as the company's Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Polverino was at Kite Pharma, which was acquired by Gilead Sciences in 2017.

    Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody that has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01)[1][2][3[[4] as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.

    In our program today Hofland asks Polverino about his work in oncology, his work before joining Zymeworks, and the work he and his co-workers are doing at Zymeworks.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    Reference
    [1] A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers - NCT04466891
    [2] A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer - NCT04224272
    [3] A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer - NCT03929666
    [4] A Dose-Finding Study of ZW49 in Patients With HER2-Positive Cancers - NCT03821233

    • 46 min
    A New Way to Prevent Colon Cancer: A Conversation with Check-Cap's Yoav Kimchy, Ph.D.

    A New Way to Prevent Colon Cancer: A Conversation with Check-Cap's Yoav Kimchy, Ph.D.

    In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Yoav Kimchy, Ph.D.

    Kimchy has more than 20 years of experience in the development and management of innovative medical device companies. He founded Check-Cap in 2005 and served as the company's Chief Technology Officer.

    Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer screening/ through the introduction of C-Scan®, the first patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer. The new screening technology is being designed to enable early intervention and cancer prevention.

    The capsule-based screening technology is expected to significantly increase screening adherence worldwide, and help millions of people to stay healthy through preventive colorectal cancer screening.

    The technology is based on an ultra-low-dose X-ray capsule, an integrated positioning, control, and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract.

    One of the benefits of the technology is that it is non-invasive and requires no sedation. And unlike other capsule technologies, it requires no preparation, allowing the patients to continue their daily routine without interruption.

    An important caveat is that the technology is not intended to replace a colonoscopy. In the program, Kimchy argues that at all times a positive result should be followed by colonoscopy.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 40 min
    Advancing the Diagnosis and Treatment of Ductal Carcinoma in Situ (DCIS)

    Advancing the Diagnosis and Treatment of Ductal Carcinoma in Situ (DCIS)

    In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Leonard Farber, MD, a board-certified Radiation Oncologist, and healthcare executive. Farber is recognized for his ability to identify ground-breaking technologies and position them for success in clinical practice. He recently joined EHMET Health, an emerging medical device company with a state-of-the-art device for providing radiation as a treatment for breast cancer, Farber joined the company as the Chief Medical Officer and Executive Vice President of Clinical Research. Farber also works with a large number of pioneering startups focusing on health and medicine, including establishments such as PreludeDx.

    In today’s program, Hofland and Farber talk about Ductal Carcinoma in Situ or DCIS and DCISionRT, the only risk assessment test for patients with this disease, that predicts radiation therapy benefit.

    Ductal Carcinoma in Situ
    In the US, over 60,000 women are newly diagnosed with ductal carcinoma in situ or DCIS each year, accounting for an estimated 18 – 25% of the total number of newly diagnosed breast tumors. Fortunately, DCIS is a highly curable disease with a 10-year cancer-specific survival of about 97%. Because DCIS is a "forerunner" of invasive breast cancer – and is often referred to as a pre-cancer - early diagnosis and treatment are crucial for reducing the risk of developing invasive breast cancer.

    Current treatment strategies include breast-conserving surgery with radiotherapy, breast-conserving surgery alone, mastectomy or observation.

    A recent study demonstrated that 53% of DCIS patients' risk scores were under classified and 34% were overclassified using traditional methods, resulting in overtreatment or undertreatment.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 46 min
    Increasing Awareness of Colorectal Cancer: Changing Colonoscopy Prep

    Increasing Awareness of Colorectal Cancer: Changing Colonoscopy Prep

    In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Dr. William R. Stern, M.D., a board-certified gastroenterologist and Fellow of the American College of Gastroenterology, at the Capital Digestive Care group outside of Washington, DC, about advancements in colorectal cancer screening. Also joining us today is Sue Spielberg, a patient of the Capital Digestive Care group.

    At the beginning of National Colorectal Cancer Awareness month, we talk about colorectal cancer and the prevention of this form of cancer.

    One of the best screening tools to help prevent colon or colorectal cancer is a colonoscopy. And colonoscopies are highly effective screening tools – considered the ‘gold standard’ - used to not only detect colon cancer, rectal cancer, and other conditions – but to actually help prevent these conditions from developing.

    Colonoscopies are very safe, but not completely without risk. However, and this is what every gastroenterologist, every oncologist, and in fact, every physician will tell you, … colonoscopies are done every day by experienced physicians… But more importantly… they will tell you that your chances of getting colon or colorectal cancer far outweigh the possibility of complications from a colonoscopy.

    In the program, Hofland, Stern, and Spielberg talk about one of the issues most patients undergoing a colonoscopy may find hard to deal with… It is what happens before the actual procedure: the preparation or prep.

    With the HyGIeaCare® System, physicians can offer their patients a simpler and easier bowel prep for a colonoscopy.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 42 min

Customer Reviews

3.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Science